Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study
2008

Antibiotics for Ventilator-Associated Tracheobronchitis

Sample size: 58 publication 10 minutes Evidence: moderate

Author Information

Author(s): Nseir Saad, Favory Raphaƫl, Jozefowicz Elsa, Decamps Franck, Dewavrin Florent, Brunin Guillaume, Di Pompeo Christophe, Mathieu Daniel, Durocher Alain, the VAT Study Group

Primary Institution: CHRU de Lille

Hypothesis

In patients with VAT, antibiotic treatment would be associated with reduced duration of mechanical ventilation.

Conclusion

In patients with VAT, antimicrobial treatment is associated with a greater number of days free of mechanical ventilation and lower rates of VAP and ICU mortality.

Supporting Evidence

  • Mechanical ventilation-free days were significantly higher in the antibiotic group than in the no antibiotic group.
  • Subsequent VAP rates were significantly lower in the antibiotic group.
  • ICU mortality rates were significantly lower in the antibiotic group.

Takeaway

Giving antibiotics to patients with a lung infection while on a ventilator helps them spend more days off the ventilator and reduces the chances of getting worse infections.

Methodology

A prospective, randomized, controlled, unblinded, multicenter study where patients were assigned to receive or not receive intravenous antibiotics for 8 days.

Potential Biases

The study was not blinded, and antibiotic treatment was not standardized across all patients.

Limitations

The trial was stopped early due to significant differences in ICU mortality, leading to an imbalance in group sizes and potential type I error.

Participant Demographics

Patients were adults over 18 years old with a first episode of VAT diagnosed more than 48 hours after starting mechanical ventilation.

Statistical Information

P-Value

P < 0.001 for mechanical ventilation-free days; P = 0.011 for subsequent VAP; P = 0.047 for ICU mortality.

Confidence Interval

OR 0.17 (95% CI 0.04 to 0.70) for subsequent VAP; OR 0.24 (95% CI 0.07 to 0.88) for ICU mortality.

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/cc6890

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication